Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

about

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Item

http://www.wikidata.org/entity/Q50421953

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Defining therapy goals for maj ...... f the randomized CML Study IV.

@en

Defining therapy goals for maj ...... f the randomized CML Study IV.

@nl

type

Item

label

Defining therapy goals for maj ...... f the randomized CML Study IV.

@en

Defining therapy goals for maj ...... f the randomized CML Study IV.

@nl

prefLabel

Defining therapy goals for maj ...... f the randomized CML Study IV.

@en

Defining therapy goals for maj ...... f the randomized CML Study IV.

@nl

P1476

Defining therapy goals for maj ...... f the randomized CML Study IV.

@en

P2093

Andreas Neubauer

http://www.w3.org/2001/XMLSchema#string

Christiane Falge

http://www.w3.org/2001/XMLSchema#string

Cornelius F Waller

http://www.w3.org/2001/XMLSchema#string

Dominik Heim

http://www.w3.org/2001/XMLSchema#string

Frank Stegelmann

http://www.w3.org/2001/XMLSchema#string

Joerg Hasford

http://www.w3.org/2001/XMLSchema#string

Katharina Kohlbrenner

http://www.w3.org/2001/XMLSchema#string

Lothar Kanz

http://www.w3.org/2001/XMLSchema#string

Markus Pfirrmann

http://www.w3.org/2001/XMLSchema#string

Martin C Müller

http://www.w3.org/2001/XMLSchema#string

P2860

The concept of treatment-free remission in chronic myeloid leukemia

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukemia data

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

P2888

s41375-018-0055-7

P304

1222-1228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41375-018-0055-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elisabeth Oppliger Leibundgut

P577

2018-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29479070

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

5940636

http://www.w3.org/2001/XMLSchema#string